Stock itci.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting ...Despite the negative momentum in the past three months at -12.40%, the 6 and 9-month momentum are positive at +19.58% and +14.86% respectively, contrasting slightly with the stock's minor decline ...Notably, institutional investors and hedge funds currently own approximately 85.70% of ITCI stock. This demonstrates their trust in Intra-Cellular Therapies’ ability to revolutionize treatment options for neuropsychiatric and neurological disorders. On Friday, ITCI shares opened at $62.27. The firm has maintained a 50-day moving average price ...Mar 28, 2023 · The stock is down more than 12% over the past 12 months but up more than 2% so far in 2023. ... (ITCI) Q3 2021 Earnings Call Transcript. Why Intra-Cellular Therapies Was Weak This Week.

ITCI stock rallied 2.2% Friday. Inspire Medical Systems ( INSP ) posted a weekly gain despite three losing days, gaining 3.8% Friday. INSP shares formed a handle and flirted with the 277.28 buy ...

Disruption hit MTR services to Hong Kong’s airport for about an hour on Sunday, because of a fault with the baggage handling system at Airport station. Services were back to normal by 1.25pm. The total journey time on the Airport Express from Hong Kong station to AsiaWorld-Expo station was extended by five to 10 minutes, according to …

sdominick. Introduction. Intra-Cellular Therapies (NASDAQ:ITCI), a pioneering biotech firm, is dedicated to the creation and market introduction of novel small molecule therapies, which are ...The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.67. ITCI has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday ...Intra-Cellular Therapies Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ITCI updated stock price target summary.Intra-Cellular Therapies, Inc. (ITCI) Stock Price, Quote & News - Stock Analysis NASDAQ: ITCI · IEX Real-Time Price · USD -0.01 (-0.02%) Nov 15, 2023, 4:00 …The 13 analysts offering 1 year price forecasts for ITCI have a max estimate of — and a min estimate of —. Analyst rating Based on 13 analysts giving stock ratings to ITCI in the past 3 months.

Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...

$-1.63 Market Cap $5.46 B Shares Outstanding 96.24 M Public Float 93.82 M Yield ITCI is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23)...

A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.ITCI Profile Stock Screener Earnings Calendar Sectors Nasdaq | ITCI U.S.: Nasdaq Intra-Cellular Therapies Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023... Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ... Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.NasdaqGS:ITCI Insider Trading Volume December 3rd 2023. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket. Insiders At Intra-Cellular Therapies Have Sold Stock Recently . The last quarter saw substantial insider selling of Intra-Cellular Therapies shares.Over the past five years, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has witnessed a stock price increase of 162.29%. ... Don’t go anywhere, rather, stay in the stock market, ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...

NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced a poster presentation on its PDE1 inhibitor program at the ongoing 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held from April 10 - 15, 2021.Mar 29, 2023 · ITCI stock shot up to approximately $55 per share after the success of study 403. There is some overhead supply to work through to reach new all-time highs and continued strong sales momentum and ... At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Real time Intra-Cellular Therapies (ITCI) stock price quote, stock graph, news & analysis. TipRanks | Stock Market Research, News and Analyst Forecasts ...

Intra-Cellular Therapies, Inc. (ITCI) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 62.84 +1.47 (+2.40%) At close: 04:00PM EST. 60.44 -2.40 (-3.82%) After hours:...

Get Intra-Cellular Therapies Inc (ITCI.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsBiotech Alert: Searches spiking for these stocks today May 5, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Phibro Animal Health (PAHC) and ...Nov 28, 2023 · Nov. 08. CI. RBC Trims Price Target on Intra-Cellular Therapies to $76 From $77, Keeps Outperform Rating. Nov. 03. MT. Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M. Nov. 02. MT. Transcript : Intra-Cellular Therapies, Inc., Q3 2023 Earnings Call, Nov 02, 2023. Nov 24, 2023 · So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. -36.92% -224.88% NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, …Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.ITCI, -14836.0 shares, $-823694.72, 2023-08-31, N-PORT. No recent transactions ... Stock Lookup. Enter stock name: use * for wildcard.ITCI reported total revenues of $126.2 million for Q3 2023, compared to $71.9 million for the same period in 2022. ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can ...The average twelve-month price prediction for Intra-Cellular Therapies is $78.67 with a high price target of $101.00 and a low price target of $62.00. Learn more on ITCI's analyst rating history. Do Wall Street analysts like Intra-Cellular Therapies more than its competitors?04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ...

Get the latest stock price for Intra-Cellular Therapies Inc. (ITCI:US), plus the latest news, recent trades, charting, insider activity, ...

View the basic ITCI option chain and compare options of Intra-Cellular Therapies, Inc. on Yahoo Finance.

Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ITCI stock stock is $78.5, which predicts an increase of 34.05%. The lowest target is $62 and the highest is $101. On average, analysts rate ITCI stock stock as a strong buy.0001193125-20-288507.txt : 20201109 0001193125-20-288507.hdr.sgml : 20201109 20201109074552 ACCESSION NUMBER: 0001193125-20-288507 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTITCI - Free Report) shares were up 2% on May 5, after the company reported better-than-expected first-quarter 2023 results on May 4. ITCI incurred a loss of 46 cents per share in the reported ...Nov 24, 2023 · Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Intra-Cellular Therapies, Inc. (ITCI) Stock Price, Quote & News - Stock Analysis NASDAQ: ITCI · IEX Real-Time Price · USD -0.01 (-0.02%) Nov 15, 2023, 4:00 …Wall Street expects a year-over-year increase in earnings on higher revenues when Intra-Cellular Therapies (ITCI) reports results for the quarter...May 4, 2023 · Intra-Cellular: Q1 Earnings Snapshot. NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Thursday reported a loss of $44.1 million in its first quarter. The New York-based company said it had a loss of 46 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by ... Notably, institutional investors and hedge funds currently own approximately 85.70% of ITCI stock. This demonstrates their trust in Intra-Cellular Therapies’ ability to revolutionize treatment options for neuropsychiatric and neurological disorders. On Friday, ITCI shares opened at $62.27. The firm has maintained a 50-day moving average price ...Mar. 1, 2023, 07:55 AM. In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Intra-Cellular Therapies ( ITCI – Research Report ), with a price target ...

Dec 1, 2023 · The average price recommended by analysts for Intra-Cellular Therapies Inc (ITCI) is $77.54, which is $16.26 above the current market price. The public float for ITCI is 93.65M and currently, short sellers hold a 3.65% of that float. On December 01, 2023, ITCI’s average trading volume was 845.52K shares. Top 5 EV Tech Stocks to Buy for 2023. Nov 24, 2023 · So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. -36.92% -224.88% Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.The Zacks Consensus Estimate for ITCI's full-year earnings has moved 14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Instagram:https://instagram. zurp credit cardcampbell wealth management5 year treasury billrenter's insurance boston Wasatch Global Investors highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc ...0001193125-20-261367.txt : 20201001 0001193125-20-261367.hdr.sgml : 20201001 20201001163855 ACCESSION NUMBER: 0001193125-20-261367 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20200929 ITEM INFORMATION: Departure of Directors or Certain Officers; … under armour share pricelilly stock forecast Briefing From The Editor -- ITCI Stock. Now trading at a price of $49.82, Intra-Cellular Therapies has moved 0.1% so far today. Intra-Cellular Therapies returned gains of 9.0% last year, with its stock price reaching a high of $67.05 and a low of $42.01. Over the same period, the stock underperformed the S&P 500 index by -4.0%.Intra-Cellular Therapeutics ITCI incurred a loss of 45 cents per share in fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 62 cents. The reported loss per share is also ... sl green realty stock Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.View the latest Intra-Cellular Therapies Inc. (ITCI) stock price, news, historical charts, analyst ratings and financial information from WSJ. ITCI - place your bets With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch. There is however always a possibility of CRL from the FDA, if th With a huge …